BioNTech SE (NASDAQ:BNTX) Shares Bought by TD Asset Management Inc

TD Asset Management Inc lifted its position in shares of BioNTech SE (NASDAQ:BNTX) by 6.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,590 shares of the company’s stock after buying an additional 435 shares during the period. TD Asset Management Inc’s holdings in BioNTech were worth $612,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. Primecap Management Co. CA raised its holdings in BioNTech by 2.8% in the 4th quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock valued at $502,735,000 after buying an additional 131,490 shares during the period. Harding Loevner LP acquired a new stake in shares of BioNTech during the fourth quarter valued at about $410,984,000. Capital World Investors raised its stake in shares of BioNTech by 0.5% in the 1st quarter. Capital World Investors now owns 943,116 shares of the company’s stock valued at $87,002,000 after acquiring an additional 4,369 shares during the period. Clearbridge Investments LLC lifted its holdings in shares of BioNTech by 4.7% in the 4th quarter. Clearbridge Investments LLC now owns 506,692 shares of the company’s stock worth $53,476,000 after acquiring an additional 22,566 shares during the last quarter. Finally, Bamco Inc. NY boosted its position in shares of BioNTech by 3.7% during the 1st quarter. Bamco Inc. NY now owns 251,223 shares of the company’s stock worth $23,175,000 after purchasing an additional 8,875 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on BNTX shares. Jefferies Financial Group boosted their target price on BioNTech from $90.00 to $96.00 and gave the company a “hold” rating in a research report on Friday. HSBC raised BioNTech from a “hold” rating to a “buy” rating in a research note on Friday, August 2nd. Hsbc Global Res raised BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. TD Cowen cut their price target on shares of BioNTech from $98.00 to $85.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of BioNTech from a “hold” rating to a “buy” rating and set a $95.00 price objective for the company in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, six have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $108.00.

BioNTech Stock Up 17.5 %

BNTX stock opened at $123.40 on Monday. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $125.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40. The company has a market cap of $29.34 billion, a price-to-earnings ratio of 246.80 and a beta of 0.23. The company has a fifty day moving average price of $87.28 and a 200 day moving average price of $89.66.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The business had revenue of $128.70 million during the quarter, compared to analysts’ expectations of $134.98 million. During the same period in the previous year, the company posted ($0.86) earnings per share. BioNTech’s quarterly revenue was down 23.3% on a year-over-year basis. Sell-side analysts expect that BioNTech SE will post -2.8 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.